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1. Introduction 
A well documented genetic deficiency of an 
enzyme post-translationally acting on specific peptidyl 
amino acids occurs in Ehlers-Danlos syndrome type 
VI, clinically characterized by ocular fragility, severe 
progressive scoliosis, hyperextensible skin, marked 
joint laxity with recurrent dislocations, and easy 
bruising [1 ]. In skin, the biochemical marker of this 
autosomal recessively inherited syndrome is a reduc- 
tion of the Hyl level with an unaffected Hyp concen- 
tration [2-71. In fibroblast cultures, only the Hyl 
content but not the Hyp content of collagen (types 
1,111) is lowered f&7], the activity of the Hyl syn- 
thesizing enzyme being -10% of normal. The activity 
of the Hyp producing prolylhydroxylase (EC 
1.14.11.2) is unaffected [2-91. As hydroxylysyl- 
derived crosslinks of collagen are more stable than 
those derived from lysyl residues [lo], and as the 
number and chemical nature of the crosslinkages in 
collagen from Ehlers-Danlos syndrome type VI 
patients differ totally from the normal pattern with a 
concomitant increase in solubility [ 111, the diminished 
activity of lysylhydroxylase (EC 1.14.11.4.) has been 
proposed as the molecular basis of this inherited 
connective tissue disease [ 121. 
Address correspondence to: H. hf. Hanauske-Abel, Kinder- 
klinik der Universitlt, 65 Mainz, FRG 
Nomenclature: Designations recommended by the WHO Com- 
mittee on Complement Nomenclature (1970) Immunochem- 
istry 7, 137 
Abbreviations: Hyp, 4-transhydroxyproline; Hyi, erythro-fi- 
bydroxylysine; EDTA, ethylene diaminetetraacetic acid; 
VBS-S, Verona1 buffered saline-sucrose 
ElsevierjNorth-Ho~~nd Biomedical Press 
C 1 q contains a collagen-like sequence of -80 
amino acid residues which imparts to this serum pro- 
tein some of the biophysical and biochemical charac- 
teristics of collagen [13- 161. Both Cl r and Cl s 
interact with Clq through its collagen microfibril-like 
part, constituting the first complement component 
C 1; selective destruction of the collagenous triple 
helical structure within Clq obviates this association 
[ 17- 193. Following the bind~g of immune com- 
plexes to the non-collagenous heads of Clq, a con- 
formational change is thought o occur in its colla- 
genous tail resulting in the activation of C 1 r-Cl s 
and consequently of the entire complement cascade 
u31. 
We undertook this study of the classical pathway 
of complement in a family affected by Ehlers-Danlos 
syndrome type VI to determine whether, in addition 
to the documented abnormalities in interstitial col- 
lagens, the structure or function of the collagenous 
part of C 1 q is impaired. 
2. Materials and methods 
2.1. Amino acid analysis of euglobulins 
Venous blood was allowed to clot at 4°C. After 
centrifugation, serum was stored at -25°C. Serum 
was diluted I:8 with deionized water at O*C and 
adjusted to pH 5.6 with 1 N HCl under constant 
stirring. After 12 h, the precipitate was collected 
(15 000 rev./min, 45 min, 4°C) washed in 0.02 M 
acetate buffer (PH 5.6) and defatted in acetone. The 
final precipitate was dried. Samples were hydrolysed 
in 2 ml constant boiling 6 N HCl at 1lO’C for 22 h 
under nitrogen in sealed tubes. The acid was removed 
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under vacuum and the samples used for amino acid 
analysis on a Beckman Multichrom C analyser. Hyp 
was developed from a 0.9 X 52 cm column (Beckman 
M 72 resin) with a 0.2 N Na-citrate buffer (pH 3.15) 
at 3O”C, while Hyl was eluted from a 0.9 X 12 cm 
column with 0.2 N Na-citrate, 1 N NaCl (pH 6.28) at 
55°C. 
2.2. Hemoly tic assay of complemen t camponen ts 
The measurement of whole serum hemolytic com- 
plement (CH50) was performed by the standard pro- 
cedure [20]. The functional activity of the individual 
components Cl $4 and C2 was determined using 
erythrocytes in the state EAC4, EACI and EAC14. 
The details for the preparation of these intermediates, 
the appropriate buffers and the titration proper are 
given in [2 11. The functional assay for Cl q was per- 
formed on serum samples diluted 1: 1 in 0.05 M 
EDTA. 0.1 ml of this mixture was incubated with 0.1 
ml EA (I .3 X IO8 cells/ml) for 15 min at 30°C. Then 
the cells were washed twice and resuspended in 0.2 
ml VBS-S in the presence of 0.1 ml recalcified RClq 
for 15 min at 30°C. This reagent, source for Clr and 
Clr, was prepared according to [22]. The cells were 
washed again, sensitized with C4 and subsequently 
treated as detailed for the Cl test. Guinea pig Cl was 
functionally purified as in [23]. C4 and C2 were pur- 
chased from Cordis Co., Miami, FL. Guinea pig serum 
served as source for C-EDTA. 
3. Results 
3.1. Analytical data 
All the Clq in serum precipitates with the euglo- 
bulin fraction in which it is the only protein con- 
taining post-translationally hydroxylated amino acid 
residues [24]. For determination of the Hyl/Hyp 
Table 1 
HyllHyp ratios 
Literature 
Cl¶ 
0.46a 
0.53b 
Skin collagen 
0.06’ 
Control 0.52 
Patient 0.48 
Mother 0.61 
Father 0.44 
a Purified according to [ 30 ] 
b Purified according to [ 3 1 ] 
C [251 
d Calculated from the data in [ 71 
0.053d 
No Hyld 
0.022d 
0.022d 
ratio it is therefore sufficient to analyse the euglo- 
bulins. Moreover, this coefficient is independent of 
varying Cl q concentrations in the different euglobulin 
preparations. In collagen biochemistry, this parameter 
has been used for the differentiation of interstitial 
collagen types [25] and for the study of the Hyl con- 
tent in tissues from Ehlers-Danlos syndrome type VI 
patients [2]. As expected (table l), the Hyl/Hyp ratio 
found in the control euglobulin fraction equals the 
values for purified human Cl q calculated from the 
data of different authors. A significant diminution of 
the coefficient in the euglobulins of the probands 
could not be established. The values for the homozy- 
gouspatient, the heterozygous mother and the hetero- 
zygous father were close to the control and to the 
ratio reported for purified human Clq. Thus, in this 
Ehlers-Danlos type VI family the structural integrity 
of the collagen-like part within C 1 q appears to be 
unaffected. The hydroxylation of lysyl residues in 
this serum protein is unaltered, irrespective of the 
homo- or heterozygous state for lysylhydroxylase 
deficiency in fibroblasts. 
Table 2 
Activity of whole complement and of individual complement components 
Parameter 
CH50 (U/ml) 
(Eff. mol./ml) 
Control 
30.3 
Patient 
29.3 
Mother 
29.5 
Father 
28.3 
Clq (X 10’3) 0.21 0.19 0.23 0.18 
Cl (X 10-j 3.1 3.0 3.4 3.2 
c4 (X 10’3) 1.7 1.4 1.6 1.9 
c2 (X 1O’O) 2.8 1.6 1.4 1.4 
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3.2. Functional data 
The whole serum hemolytic complement, measured 
in terms of CH50 units, and the hemolytic assays of 
the individual classical pathway components Clq,Cl 
and C4 did not show a reduction. Table 2 demon- 
strates that Clq and Cl are unaffected in their activi- 
ties. C2 in these three sera, however, reached <60% 
of the control value. The data for C 1 q indicates that 
the ability to utilize C 1 r and C 1 s, offered externally 
in the form of RCl q, is unaffected. 
4. Discussion 
The family whose Clq we investigated here was 
the subject of a connective tissue study [7] bio- 
chemically characterizing the dermal collagen of the 
3 year old boy and his parents. These findings led to 
the diagnosis of Ehlers-Danlos syndrome type VI in 
the boy as his skin collagen revealed a complete lack 
of hydroxylysine, while that of his parents contained 
only 50% the amount found in healthy individuals. 
The Hyl/Hyp ratios calculated from these data are 
also given in table 1. 
In this autosomal recessively inherited, hydroxy- 
lysine-deficient collagen disease an analytical and 
functional study of Cl q suggested itself for several 
reasons. 
(1) Fibroblasts produce and secrete Clq [26], and 
these cells synthesizing most of the interstitial 
collagen were supposed to be a major source of 
the Cl hemolytic activity in serum [27]. 
(2) In contrast to dermal collagen, for which a half- 
life of -60 days was found [28], the Clq turn- 
over is rapid with a daily plasma pool fractional 
catabolism of 65% [29]. 
(3) As the hydroxylysine content of the collagen- 
like part within C 1 q is exceptionally high 
[30-321, the Hyl/Hyp index represents a sensitive 
indicator for the level of hydroxylysine in Cl q. 
Hence, a diminution of the lysylhydroxylase activity 
in fibroblasts, marker for Ehlers-Danlos syndrome 
type VI, should result in a clear cut effect on the 
parameters measured here. 
Surprisingly, we did not find any compositional or 
functional alteration of Clq, in the homocygotic 
patient or in the heterocygotic parent serum (see 
tables 1,2). 
Three explanations seem worth considering: 
(1) A mutation of the structural gene affects the activ- 
ity of lysylhydroxylase towards collagen, but 
not towards Clq. This might be due to an alter- 
ation in its substrate binding site, or subsites, or 
due to a change in the requirement for cofactors, 
e.g., ascorbate. A lowered affinity of the mutant 
enzyme for vitamin C has been reported [33], and 
a concomitant reduction in enzyme activity in 
vivo could, for structural reasons, preferentially 
be reflected in collagen. 
(2) A mutation of the regulator gene reduces the 
number of the catalytically active lysylhydroxyl- 
ase molecules, upsetting the balance with prolyl- 
hydroxylase. Consequently, collagen becomes 
triple helical before the hydroxylation of lysyl 
residues is completed. As the triple helical con- 
formation prevents further hydroxylation of lysyl 
residues [39], the Hyl/Hyp ratio will remain low. 
The rate of triple helix formation of cartilage 
type II collagen is slower than that of skin type I, 
leaving more time for Hyl synthesis [34]. In fact, 
in a patient suffering from Ehlers-Danlos syn- 
drome type VI the Hyl/Hyp ratio of cartilage was 
normal while that of skin was significantly 
lowered [2]. A slow rate of triple helix formation 
might occur in Clq synthesis, too. Interestingly, 
the collagen-like regions of Cl q are bent halfway 
along their length as in one of the peptide chains 
a glycine residue in the typically collagenous 
sequence -X-Y-Gly- is replaced by alanine 
[35], producing a distortion of the triple helix 
and possibly a delay in its formation. 
(3) An isoenzyme of lysylhydroxylase may exist spe- 
cific for C 1 q synthesizing cells that is unaffected 
by the genetic defect occuring in collagen syn- 
thesizing cells. Such a dissociation of Cl q bio- 
synthesis from collagen biosynthesis also is sug- 
gested by the C 1 q insensitivity to acute vitamin C 
deficiency in guinea pigs [36]. Clq and Cl struc- 
turally and functionally remained unaffected, 
while the interstitial collagen synthesis was 
markedly impaired due to the reduction in the 
abcorbate-dependent prolylhydroxylase activity. 
Nevertheless, direct inhibition of prolylhydroxyl- 
ase in Clq synthesizing cells from guinea pigs 
stops Clq secretion [37] and demonstrates a 
conformation-dependent barrier in these cells 
[38] that is well-known from inhibition studies 
of prolylhydroxylase in collagen synthesizing 
cells: the secretion of Hyp-deficient protein is 
reversibly stopped at 37”C, but resumed at 20°C 
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where the triple helical conformation is stable 
independent of the Hyp content. 
We interpret the data on Clq presented here and in 
[36-381 as indicating a non-identity of the post- 
translational hydroxylase activities involved in the 
biosynthesis of Cl q and of collagen. 
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